Oculis (OCS) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
6 Aug, 2026Executive summary
Advanced Privosegtor as lead late-stage asset in neuro-ophthalmology, with PIONEER-1 trial progressing and positive FDA feedback for expansion into acute MS relapses.
Enrollment in Licaminlimab PREDICT-1 genotype-based trial for dry eye disease surpassed 45%, with all sites activated and topline results expected around year-end.
Strong cash position of $282.3 million as of June 30, 2026, providing runway into 2H 2029.
Financial highlights
Cash, cash equivalents, and short-term investments increased to $282.3 million from $268.7 million at year-end 2025, driven by share sales offset by operating expenses.
Research and development expenses were $19.3 million for Q2 2026, up from $18.1 million in Q2 2025.
General and administrative expenses rose to $10.9 million from $7.4 million year-over-year.
Net loss for the first half of 2026 was $49.3 million, an improvement from $67.9 million in the prior year period, mainly due to fair value gain on warrant liabilities and favorable FX.
Basic and diluted loss per share was $0.65 for the six months ended June 30, 2026, compared to $1.16 in the prior year.
Outlook and guidance
IND submission for Privosegtor in acute MS relapses planned for Q4 2026.
Topline results for Licaminlimab PREDICT-1 trial expected around year-end 2026.
Cash runway expected to last into the second half of 2029.
Latest events from Oculis
- Privosegtor advances neuroprotection while licaminlimab tests biomarker-guided dry-eye care.OCS
Stifel 2026 Healthcare Conference 2026 - PREDICT-1 readout nears as privosegtor advances across neuroprotection indications.OCS
3rd Annual Guggenheim Healthcare Innovation Conference - Late-stage trials advance as $252.0M in cash supports runway into 2H 2029.OCS
Q3 2026 - ACUITY signals support a registrational optic neuritis program for privosegtor.OCS
Euretina Innovation Spotlight (EIS) 2026 Presentation - TNFR1-guided dry-eye development targets greater benefit in biomarker-positive patients.OCS
Study presentation - Phase III programs in dry eye and optic neuritis advance, with MS and NAION expansion planned.OCS
2026 Global Healthcare Conference - Precision medicine and targeted trials drive clinical and commercial strategy, with strong funding.OCS
H.C. Wainwright 28th Annual Global Investment Conference - Late-stage neuro-ophthalmic and ophthalmic programs advance toward pivotal milestones with strong financial backing.OCS
Corporate presentation - Positive clinical results and precision medicine advances set the stage for major milestones in 2024–2025.OCS
H.C. Wainwright 26th Annual Global Investment Conference